Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib 300 mg in Japanese Patients With Unresectable or Metastatic Medullary Thyroid Carcinoma
jRCT2080221951Phase 2
- Sponsor
- AstraZeneca
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vandetanib in Medullary Thyroid Cancer (MTC), sponsored by AstraZeneca.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on jRCT2080221951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221951.